Ovarian cancer: Innovative research approach identifies target proteins for potential anti-tumor drug rhenium tricarbonyl (TRIP)
Scientist of the Institute Krems Bioanalytics at IMC Krems uses chemoproteomics to discover the scaffold protein NUBP2 as a promising candidate. Krems, Austria, 17. January 2023: Using an innovative research method, the identification of target proteins for the potential anti-tumor drug rhenium tricarbonyl (TRIP) in ovarian cancer cells was successfully achieved. Of the 89 proteins […]